Revenue
2019
2020
2021
2022
2023
2024
2025
Biomerieux (BIM)
Price€71.70Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | €4.07B | €3.98B | €3.67B | €3.59B | €3.38B | €3.12B | €2.67B |
| Gross profit | €2.31B | €2.22B | €2.06B | €2.01B | €2.00B | €1.75B | €1.47B |
| Gross margin | 56.73% | 55.66% | 55.99% | 55.97% | 59.26% | 56.24% | 54.83% |
| Research & development | €507.4M | €491.5M | €460.1M | €446.6M | €385.8M | €398.8M | €374.3M |
| Operating expenses | €1.79B | €1.63B | €1.62B | €1.42B | €1.22B | €1.20B | €1.10B |
| Operating income | €521.3M | €588.8M | €439.0M | €587.2M | €784.3M | €552.8M | €370.7M |
| Operating margin | 12.81% | 14.79% | 11.95% | 16.36% | 23.23% | 17.73% | 13.86% |
| EBITDA | €848.6M | €855.9M | €657.4M | €797.2M | €973.3M | €763.6M | €560.2M |
| EBITDA margin | 20.85% | 21.51% | 17.89% | 22.21% | 28.83% | 24.49% | 20.94% |
| Net income | €396.9M | €425.1M | €322.8M | €440.5M | €598.2M | €402.7M | €269.7M |
| Net profit margin | 9.75% | 10.68% | 8.78% | 12.27% | 17.72% | 12.91% | 10.08% |
| Basic EPSper basic share | €3.37 | €3.67 | €3.03 | €3.84 | €5.08 | €3.42 | €2.31 |
| Diluted EPSper diluted share | €3.34 | €3.64 | €3.01 | €3.82 | €5.06 | €3.41 | €2.30 |